title: Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion.
abstract: Neurotensin (NT) has been proposed as an endogenous antipsychotic based in part on the similarity in behavioural effects to antipsychotic drugs, for example, attenuation of both amphetamine-induced hyperlocomotion (AH) and amphetamine disrupted pre-pulse inhibition in the rat. However, there is some evidence that repeated administration of NT or an analogue produces behavioural tolerance to such effects. The present experiments sought to confirm and extend these findings by testing the effects on AH of 7 days central administration of NT and the NT1 selective analogue PD 149163 and the effects of 21 days central administration of NT. NT and PD149163 continuously administered for 7 days produced no effect on AH (in contrast to attenuation with a single injection here and previously reported), whereas 21 days of NT administration potentiated AH. Together, these studies report that the effects of NT or a NT analogue on AH depends on the duration of administration of peptide. The results are discussed in comparison with the reported antipsychotic properties of acute administration of NT and possible mechanisms involving NT1 receptors.
authors.affiliation: Division of Psychology, Nottingham Trent University, Burton Street, Nottingham, UK. christine.norman@ntu.ac.uk
authors.forename: C
authors.initials: C
authors.lastname: Norman
authors.forename: S R G
authors.initials: SR
authors.lastname: Beckett
authors.forename: C H
authors.initials: CH
authors.lastname: Spicer
authors.forename: D
authors.initials: D
authors.lastname: Ashton
authors.forename: X
authors.initials: X
authors.lastname: Langlois
authors.forename: G W
authors.initials: GW
authors.lastname: Bennett
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D004357:Drug Synergism; D007276:Injections, Intraventricular; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D011863:Radioimmunoassay; D051381:Rats; D018028:Receptors, Neurotensin / Q000819:agonists*
chemical_list: D000697:Central Nervous System Stimulants; C117269:PD 149163; D018028:Receptors, Neurotensin; C114036:neurotensin type 1 receptor; D009496:Neurotensin; D000661:Amphetamine